Axsome Therapeutics (AXSM) director awarded 1,721 RSUs vesting in one year

Rhea-AI Filing Summary

Saad Mark E reported acquisition or exercise transactions in this Form 4 filing.

Axsome Therapeutics, Inc. director Mark E. Saad received a grant of 1,721 restricted stock units on June 5, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest in full on the one-year anniversary of the grant date.

Insights

Equity compensation analyst

Director received a routine RSU grant that vests after one year.

Director Mark E. Saad was awarded 1,721 restricted stock units, each convertible into one share of Axsome Therapeutics, Inc. common stock. The grant price is shown as $0.0000, consistent with equity compensation rather than a market purchase.

The filing states these RSUs vest in full on the one-year anniversary of the grant date, so the units are contingent until that time. After vesting, they can settle into common shares, modestly increasing Saad’s equity exposure while aligning incentives with shareholder outcomes.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Saad Mark E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	1,721	$0.00	--

Holdings After Transaction: Restricted Stock Units — 1,721 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the one-year anniversary of the date of grant.

Key Figures

RSUs granted: 1,721 units Grant price per RSU: $0.0000 Underlying common shares: 1,721 shares +1 more

4 metrics

RSUs granted 1,721 units Restricted stock units granted to director on June 5, 2026

Grant price per RSU $0.0000 Equity compensation, not open-market purchase

Underlying common shares 1,721 shares Each RSU equals one share of common stock

RSU holdings after grant 1,721 units Total RSUs owned by Mark E. Saad following transaction

Key Terms

Restricted Stock Units, RSU, vest in full, contingent right, +1 more

5 terms

Restricted Stock Units financial

"security_title: "Restricted Stock Units""

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU financial

"Each restricted stock unit ("RSU") represents a contingent right"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

vest in full financial

"The RSUs vest in full on the one-year anniversary"

contingent right financial

"represents a contingent right to receive one share"

underlying security financial

"underlying_security_title: "Common Stock""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saad Mark E

(Last) (First) (Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/05/2026		A		1,721		(2)	(2)	Common Stock	1,721	$0	1,721	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs vest in full on the one-year anniversary of the date of grant.

	/s/ Nick Pizzie, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity award did Axsome Therapeutics (AXSM) director Mark E. Saad receive?

Mark E. Saad received a grant of 1,721 restricted stock units (RSUs). Each RSU represents a right to receive one share of Axsome Therapeutics common stock, providing stock-based compensation tied directly to the company’s future share performance.

How do the new RSUs for Axsome Therapeutics (AXSM) convert into common shares?

Each RSU granted to Mark E. Saad represents a contingent right to one common share. After vesting, the RSUs can settle into Axsome Therapeutics common stock, effectively increasing his ownership if the shares are delivered and retained.

When do Mark E. Saad’s new Axsome Therapeutics (AXSM) RSUs vest?

The RSUs granted to Mark E. Saad vest in full on the one-year anniversary of the grant date. Until vesting, they remain contingent and cannot be settled into common shares, reflecting a standard time-based vesting schedule for director compensation.

How many Axsome Therapeutics (AXSM) RSUs does Mark E. Saad hold after this grant?

Following this award, Mark E. Saad is reported to hold 1,721 restricted stock units. These RSUs correspond to a potential 1,721 shares of Axsome Therapeutics common stock if and when the units vest and are settled in shares.

Was this Axsome Therapeutics (AXSM) RSU transaction an open-market purchase or sale?

No, the Form 4 shows a grant or award acquisition of RSUs, not an open-market trade. The transaction code is “A,” indicating equity compensation, with a price of $0.0000 per unit rather than a market purchase or sale.